Please login to the form below

Not currently logged in
Email:
Password:

transplants

This page shows the latest transplants news and features for those working in and with pharma, biotech and healthcare.

Gilead NASH drug clears mid-stage trial, but rivals are looming

Gilead NASH drug clears mid-stage trial, but rivals are looming

transplant. In the NASH study, 39% of patients taking a high dose of the drug once daily for 24 weeks experienced at least a 30% reduction in liver fat, compared to

Latest news

More from news
Approximately 9 fully matching, plus 222 partially matching documents found.

Latest Intelligence

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    That said, for thalassemia, and for sickle cell, we believe these are potentially one-time curative treatments, because these stem cell transplants have been shown to last a very long time, ... Conventional stem cell transplants cost anywhere between $500

  • Health on instalment Health on instalment

    Distasteful but…. In addition to pay-for-performance, other possible funding strategies under consideration include mandatory price limits; re-insurance (currently used for expensive transplant operations); risk pooling; and lease-like

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    way under the cost-effective price and significantly lower than the current standard of allogenic stem cell transplant that costs $500, 000-800, 000 in the first year with follow-up

  • Cell and gene therapies: on course for commercial success? Cell and gene therapies: on course for commercial success?

    Many cell therapies require additional, costly procedures for administration such as an allogeneic stem cell transplant as well as adjuvant therapies. ... Many transplant centres in England, and in other countries, are funded with a single, fixed payment

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    NASH and biosimilars. One therapeutic indication that could be seen to be gaining much attention was NASH, which is the fastest growing cause of liver cancer and liver transplant in the

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics